Athenex Announces the US FDA Allowance of the Investigational New Drug Application of Oratopo, A Combination of HM30181A and Oral Topotecan For the Treatment of Advanced Cancer

Latest clinical candidate to emerge from Athenex’s proprietary Orascovery platform Creates potential for all-oral chemotherapy treatment of numerous cancers Represents the Company’s 7th successful IND approval by the US FDA Buffalo, NY and Hong Kong – Athenex, Inc., a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for…

Athenex Inc. announces the promotion of Jeffrey M. Yordon to the position of Chief Operating Officer

Buffalo, NY – Athenex, Inc. announced today the promotion of Jeffrey M. Yordon to the position of Chief Operating Officer (COO) for the company effective upon Board approval.  Previously Mr. Yordon was the President of the Athenex Pharmaceutical Division (APD), which was focused on commercializing all of Athenex’s products and intellectual property.   Mr. Yordon…

PharmaEssentia and Athenex Agree on Product Development Rights as Part of Strategic Realignment

Buffalo, NY and Vietnam – PharmaEssentia (TSE:6446) and Athenex are pleased to announce the execution of an amendment to the prior license agreements between the two companies that provides for PharmaEssentia to acquire the rights to develop and commercialize Oraxol and Oratecan in Vietnam and for Athenex to reacquire the right to market and commercialize…

Athenex and Imuna Pharm, a.s. Enter Commercial Agreement to Market Specialty Products in the United States

Agreement will utilize Imuna’s unique manufacturing capabilities to help address market shortages and deliver innovative, cost-effective and Ready-to-Use premix IV bag products to the U.S. marketplace Buffalo, NY — Athenex, Inc. announced today a new collaboration between Athenex Pharmaceutical Division (APD) and Imuna Pharm, a.s. (Imuna) to provide specialty injectable products for the United States…

Athenex and Beijing Sciecure Pharmaceutical announce binding agreement to launch and market five injectable pharmaceutical products in North America

Buffalo, NY and Hong Kong – Athenex Pharmaceutical Division and Beijing Sciecure Pharmaceutical Co., Ltd., a specialty pharmaceutical company, today announced a binding agreement to launch and market 5 pharmaceutical products, all injectable, in the North America territory. These products are therapeutically relevant to the Athenex proprietary pipeline of products under development. The products will be…

Athenex announces Xiangxue Pharmaceuticals Company Limited, its KX-02 development partner in China, has achieved a regulatory milestone in that territory

Buffalo, NY – Athenex today announced that its development partner for KX-02, Xiangxue Pharmaceuticals Company Limited, has publicized that the Guangdong Province Food and Drug Administration (FDA) declared completion of the Investigational New Drug (IND) application for KX-02 active pharmaceutical ingredient and KX-02 Tablet and referred the IND to the Center of Drug Evaluation (CDE)…

Athenex Inc. and SunGen Pharma enter into U.S. joint venture agreement for a portfolio of 7 approved pharmaceutical products

Buffalo, NY and Hong Kong – Athenex Pharmaceutical Division and SunGen Pharma LLC, DBA Peterson Pharmaceuticals, a specialty pharmaceutical company located in New Jersey, today announced a joint venture agreement to launch and market 7 pharmaceutical products, both injectable and solid oral dosage, in the United States. Many of these products are therapeutically relevant to…

Dr. Daniel Von Hoff, MD, F.A.C.P. Joins Athenex’s Clinical Scientific Advisory Board

Buffalo, NY and Hong Kong – Athenex Inc., an innovative oncology pharmaceutical company with a broad range of proprietary oncology pharmaceutical products and product candidates under development, is pleased to welcome Dr. Daniel Von Hoff, MD, F.A.C.P. to its Clinical Scientific Advisory Board (SAB). Dr. Von Hoff is highly regarded as a medical oncologist and…